[KM 2210 therapy for chronic lymphocytic leukemia]

Two previously untreated patients with chronic lymphocytic leukemia (CLL) were treated with KM 2210 50 mg/day orally for 30 and 14 days, respectively. They showed good responses: One achieved complete, the other partial, remission. Toxicity was not observed in either patient. KM 2210 was thought to be an effective drug for CLL.